REACT: Real-world survival outcomes with atezolizumab, bevacizumab, and chemotherapy for treatment of advanced non-squamous NSCLC
Authors:
- D. I. YudinDYD. I. Yudin
- K. K. LaktionovKLK. K. Laktionov
- R. A. ZukovRZR. A. Zukov
- I. L. ObrazIOI. L. Obraz
- D. V. PerunovDPD. V. Perunov
- M. M. MagamedovaMMM. M. Magamedova
- F. V. MoiseenkoFMF. V. Moiseenko
- E. О. ElsakovaEEE. О. Elsakova
- A. V. SultanbaevASA. V. Sultanbaev
- K. V. MenshikovKMK. V. Menshikov
- M. A. ZafirovaMZM. A. Zafirova
- S. V. GamayunovSGS. V. Gamayunov
Open Access
- 1 January 2026
- journal article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 96-108
Abstract
Introduction . Atezolizumab, bevacizumab, and chemotherapy (ABCP) is a standard of care for advanced non-squamous NSCLC, including post-TKI patients with EGFR/ALK mutations. Real-world data on ABCP efficacy in Russia are limited. Aim . To evaluate OS and PFS in real-world NSCLC patients who received ≥4 cycles of first-line ABCP followed by atezolizumab-bevacizumab (AB) maintenance. Materials and methods . REACT is an observational, retrospective, multicenter study of adult patients with advanced NSCLC (diagnosed 2021–2023) who received ≥4 ABCP cycles and started AB maintenance. Key endpoints included ORR, PFS, and OS. Results . Data from 108 patients were included: 78 patients (72.2%) received ABCP in first line (wild type) and 30 (27.8%) were post-TKI (EGFR/ALK+). Median age 57.6 years; 63.9% male. Baseline metastases: CNS (17.6%), liver (8.3%), bone (33.3%). ORR was 56.5% (59.0% first line); DCR 98.2%. Median PFS was 14.7 months (95% CI 12.4–23.9) in first line group and 9.3 months (95% CI 7.4–14.6) in post-TKI group. Median OS was 34.4 months (95% CI 21.8–NR) in first line group and 24.2 months (95% CI 21.8–NR) post-TKI. 2-year OS rates were 52.7% and 54.4%, respectively. High tumor burden (≥3 sites), large sum of longest diameters, and bone metastases were negative prognostic factors. Age, sex, smoking, and PD-L1 status had no significant impact. Conclusion . In this cohort, the ABCP regimen was highly effective. Results align with IMpower150 trial for post-TKI patients and demonstrate prolonged survival in the first-line setting.Keywords
This publication has 18 references indexed in Scilit:
- Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancerEuropean Journal of Cancer, 2025
- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON TrialJournal of Thoracic Oncology, 2024
- Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialEuropean Journal of Cancer, 2024
- Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung CancerJAMA Oncology, 2024
- IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or BrainJournal of Thoracic Oncology, 2022
- IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCJournal of Thoracic Oncology, 2021
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlookCancer Treatment Reviews, 2020
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and TreatmentMayo Clinic Proceedings, 2019
- P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + BevacizumabJournal of Thoracic Oncology, 2018
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaNature Communications, 2016